Flavin-containing monooxygenases (FMOs) are major mammalian non-cytochrome P450 oxidative enzymes. T Helper2 cell-activated allergic diseases produce excess levels of nitric oxide (NO) that modify the functions of proteins. However, it remains unclear whether allergy-induced NO affects the pharmacokinetics of drugs metabolized by FMOs.
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Introduction Flavin-containing monooxygenases (FMOs) are major mammalian noncytochrome P450 oxidative enzymes (Rettie et al., 1995) , and commonly react to form N-and S-oxides of nucleophilic heteroatom-containing drugs and xenobiotics. Five FMO forms have been identified in humans and mice, and require nicotinamide adenine dinucleotide phosphate (NADPH) and oxygen. FMO expression is species-, tissue-, age-, and gender-dependent. Of interest, FMO1 form is found in the fetal human liver, however, marked changes in enzyme expression at birth result in FMO3 becoming the predominant human FMO (Dolphin et al., 1996; Koukouritaki et al., 2002) . In male and female mice, the FMO1 protein is expressed at a high level, and hepatic FMO3 protein is genderspecific to females (Cherrington et al., 1998) . Sex hormones in rats and mice regulate FMO1 and FMO3 expression (Dannan et al., 1986; Lemoine et al., 1991; Falls et al., 1997; Coecke et al., 1998) , and glucocorticoids and 17-estradiol are considered to be regulators of gene transcription in rodents and humans (Dixit and Roche 1984; Esposito et al., 2014) . FMO3 exists at levels similar to the major human liver cytochrome P450 (CYP) 3A4 (Haining et al., 1997) . Loss-of-function mutations, nonsense mutations, and missense mutations in the FMO3 gene produce phenotypes associated with the inherited disorder trimethylaminuria (Treacy et al., 1998) . FMO4 protein is expressed in liver of humans and mice (Novick et al., 2009) , however, FMO4 does not contribute significantly to drug metabolism in humans (Krueger and Williams, 2005) . Functional FMO2 is not expressed in liver of most humans (Dolphin et al., 1998) . FMO5 is highly expressed in the liver of mice (Janmohamed et al., 2004) and humans .
Only a few chemicals are known to be metabolized by mouse FMO5 (Zhang et al., 2007) and the contribution of FMO5 to liver xenobiotic metabolism is not clear. Therefore, This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on July 31, 2017 as DOI: 10.1124 at ASPET Journals on August 28, 2017 dmd.aspetjournals.org Downloaded from DMD/2017/076570 5 FMO1 and FMO3 are considered to be the most important isoforms of the FMO family with respect to the metabolism of foreign chemicals (Ziegler, 1993) .
Type I allergic diseases, such as atopic dermatitis, asthma, and allergic rhinitis, are a significant health problem. Approximately 20% of the world's population suffers from some kind of allergic disorder, with incidences continuing to rise (Warner et al., 2006) .
Concerning the allergy-inducing mechanism, T helper (Th) 2 cytokines (IL-4, IL-5 and IL-13) stimulate mast cells and eosinophils and increase allergen-specific immunoglobulin (Ig)E production. Subsequently, activated mast cells release cytokines and some inflammatory mediators (Zhu et al., 1999; Stassen et al., 2001) . Patients with bronchial asthma and allergic rhinitis show an increased level of nitric oxide (NO) in exhaled air (Alving et al., 1993; Kharitonov et al., 1997) . We also found that type 1 allergy with high serum IgE concentrations enhance serum NO concentrations (Tanino et al., 2016) . Park et al. (1999) suggested that excessive activation of the L-arginine/NO pathway (NO-dependent pathway) was responsible for the suppression of FMO activities.
However, their findings showed that NO did not react with the flavin adenine dinucleotide prosthetic group of FMO enzymes. The result differs from the formation of iron-nitrosyl complexes in CYP enzymes (Minamiyama et al. 1997 ). Since FMO3 contains 11 cysteines, one possibility remains that NO participates in S-nitrosylation and/or nitration of FMO proteins, leading to consequent reversible and/or irreversible modulation(s) of FMO activity. Concerning the contribution of Th2 cell-activated immune systems, little information is available on the ability of cytokines to directly regulate FMO1 and 3 expression. We reported that CYP1A2, CYP2C, CYP2E1, and CYP3A activities were markedly suppressed by allergy-induced NO production, but not the cytokine-dependent pathway, resulting in marked changes in drug pharmacokinetics (Tanino et al., 2016) . Our This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on July 31, 2017 as DOI: 10.1124 at ASPET Journals on August 28, 2017 dmd.aspetjournals.org Downloaded from DMD/2017/076570 6 results differed from the significant contribution of Th1 cell-activated proinflammatory cytokines (cytokine-dependent pathway) in lipopolysaccharide-stimulating inflammatory diseases (Renton 2001 (Renton , 2004 Morgan et al., 2008) . Therefore, the main aim of this study was to examine the interaction of hepatic FMO1 and FMO3 enzymes with IgE-mediated allergy-induced NO.
Materials and Methods

Materials.
Benzydamine (BDZ) was purchased from Tokyo Kasei Co., Ltd.
(Tokyo, Japan cells) on day 0 according to the methods described by Pauwels et al. (1979) and Lebrec et al. (1996) . On day 8, the mice were challenged with 2.5 g OVA (250 g/ml of saline)
by intravenous (i.v.) injection. Control mice were given single i.p. and i.v. injections of saline. At 7 days after the primary and secondary sensitization (PS7 and SS7, respectively), mice were sacrificed by decapitation. Blood was collected in heparinized tubes, and plasma was separated by centrifugation at 3000 rpm for 10 min. The liver was excised and washed three times with ice-cold 50 mM Tris-HCl (pH 7.4). Further treatments for high-performance liquid chromatography (HPLC) assay were detailed in our recent study (Tanino et al., 2016) . All animal experiments were approved by the Tokushima Bunri University Faculty of Pharmaceutical Sciences' Committee for the care and use of laboratory animals.
In separate experiments, PS7 and SS7 mice were repeatedly injected with AG (100 mg/kg/day, i.p.) from day 2 to day 7 or to day 14 after the primary sensitization. The AG dosage was determined by the in vivo data reported by Okuda et al. (1996) . The body weight of AG-treated mice did not differ from that of control mice receiving only saline (data not shown). Serum concentrations of NO2were determined using a Nitrate/Nitrite Colorimetric Assay kit (Cayman Chemical Company., An Arbor, MI) according to the manufacturer's instructions. The assay conditions were detailed in our recent report (Tanino et al., 2016) .
Assay of Total Plasma
Enzyme Assay. Liver microsomes from control and treated mice were prepared as described previously (Tanino et al., 2016) . Protein concentrations were determined with a BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Rockford, IL, USA) and
bovine serum albumin as a protein standard. Aliquots of microsomes were stored at -80 C until analysis.
Hepatic FMO1 and FMO3 activities were determined by measuring the N-oxide formation of IMP and BDZ (Narimatsu et al., 1999; Ubeaud et al., 1999) . The incubation mixtures (400 l) contained liver microsomal protein (final protein concentration, 0.5 mg/ml for IMP metabolism, 0.1 mg/ml for BDZ metabolism) from control (saline) and treated mice, a NADPH-generating system (0.2 mM NADP + , 28.6 mM MgCl2, 11.4 mM glucose-6-phoshate and 20 units/ml glucose-6-phoshate dehydrogenase), and FMO substrate (20 M IMP, or 0.5 M BDZ). All enzymatic reactions were initiated by the addition of the NADPH-generating system and were allowed to proceed at 37˚C for different times (5 min for IMP and 2 min for BDZ). Each reaction was stopped with icecold acetonitrile containing amitriptyline and talinolol as internal standards (ISs) in a HPLC assay of IMP and BDZ, respectively. Sodium hydroxide 0.1 N was added to the mixture. Subsequently, N-oxides of IMP and BDZ were extracted in ethyl acetate (Narimatsu et al., 1999) and chloroform (Ubeaud et al., 1999) , respectively, and then centrifuged at 3000 rpm for 10 min. After evaporating the organic layers, the residues This article has not been copyedited and formatted. The final version may differ from this version. were reconstituted in each mobile phase used for HPLC analysis and loaded on HPLC columns. FMO activities were expressed as metabolic formation rates of IMP N-oxide and BDZ N-oxide. Our preliminary study confirmed that the incubation time, substrate concentration, and amount of microsomes were determined to be in the linear range for metabolite formation rate.
To examine the direct interaction of hepatic microsomal FMO enzymes with NO, in vitro experiments were performed according to the method reported by Minamiyama et al (1997) . Briefly, an efficient NO donor, NOC7, dissolved in 0.1 N NaOH was added to the microsomes and NADPH-generating system at a final concentration of 1 mM. The same volume of vehicle (final concentration, 0.025% NaOH for NOC7 treatment) was added as the references. According to the method reported by Ryu et al. (2004) , the pretreated microsomes were exposed to AS at a final concentration of 10 mM. After the AS exposure, BDZ N-oxygenation was assayed under the conditions as described above.
In separate experiments, we examined S-nitrosylation of hepatic microsomal FMO1 and FMO3 enzymes in PS7 and SS7 mice. Hepatic microsomes from PS7 and SS7 mice were pre-treated with 10 mM AS in the presence of the NADPH-generating system.
Subsequently, BDZ was added, and the reaction mixtures were incubated for 5 min. Our preliminary study on S-nitrosylated FMO enzymes confirmed that NOC7 concentration, AS concentration, exposure time, substrate concentration, and amount of microsomes were determined to be in the linear range for the metabolite formation rate.
Immunoblotting.
FMO1 and FMO3 protein levels in mouse liver microsomes were determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis followed by Western blotting. In brief, hepatic microsomal proteins (50 g) were This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Hepatic Microsomal IMP and BDZ Metabolism. Imipramine is converted to imipramine N-oxide solely by FMO1 (Hernandez et al., 2009) , and BDZ is metabolized to BDZ N-oxide by recombinant FMO1 and FMO3 isoforms (Störmer et al., 2000) .
Störmer et al. (2000) showed that the rates of BDZ N-oxide formed by recombinant CYP3A, 2C, 2D6, 1A2 and 2E1 were one order of magnitude lower than that determined for recombinant FMO1 and FMO3 isoforms, implying a much minor contribution of CYP 1A ). However, the relative BDZ activity was significantly decreased to 72.8±5.2% and 68.4±5.4% by PS7 and SS7, respectively (Fig. 1B) . This finding on FMO1-dependent IMP metabolism may help to clarify FMO3-dependent BDZ N-oxide metabolism in hepatic microsomes.
Western Blot Analysis of Hepatic FMO1 and FMO3.
The expression levels of hepatic microsomal FMO1 and FMO3 proteins were investigated by Western blot analysis (Fig. 2) . In PS7 mice, protein levels of FMO1 and FMO3 enzymes were similar to those of control mice. SS7 mice had slightly reduced protein levels of FMO3, resulting in an insignificant difference between SS7 and control mice (Fig. 2B ).
FMO3 mRNA expression does not change in the liver of female mice aged 6-8 weeks (Janmohamed et al., 2004) . To determine if FMO3 protein changes at this age, we evaluated the abundance of FMO3 protein in untreated 6-8-week old female mice by Western blotting. As shown in Fig. 2C , hepatic FMO3 protein expression was not significantly different over this time period.
Hepatic iNOS and TNF- mRNA Levels.
Hepatic iNOS mRNA expression was determined by real-time polymerase chain reaction (PCR). The mRNA level of hepatic iNOS was significantly increased in sensitized mice compared with the corresponding control mice (Fig. 3A) , resulting in an average 5-fold and 15-fold times higher expression in the PS7 and SS7 mice, respectively. Further, hepatic TNF- mRNA expression was significantly enhanced by type 1 allergic diseases (Fig. 3B) . 4 ). When NOC7, an efficient NO donor, was incubated with hepatic microsomes prepared from control mice, NO overproduction did not alter IMP N-oxidation activity. In contrast, the inhibition degree of BDZ N-oxygenation activity was 36.8 ± 7.4%. To further characterize the suppression of BDZ-metabolic activity, we examined the involvement of cysteine thiols S-nitrosylation in FMO-NO interactions using AS, a sulfhydryl-reducing reagent. After the NOC7 pre-incubation with hepatic microsomes, AS treatment restored the suppression of BDZ metabolism to the control levels (Fig. 4B) .
Preventable Effect of AS on Hepatic BDZ Metabolism in Sensitized Mice. Figure 5 shows the preventable effect of AS on hepatic microsomal BDZ metabolism suppressed by type 1 allergy. When hepatic microsomes from PS7 and SS7 mice were treated with AS, BDZ N-oxygenation activity was completely restored to control levels.
Effect of iNOS Inhibitor on Allergy-Induced Serum NO Levels. Plasma total
IgE levels at 7 days after primary or secondary sensitization were significantly elevated to 6357 ± 1740 and 7799 ± 2893 ng/ml, respectively, showing 60-fold higher concentrations compared with IgE values in control mice ( Fig 6A) Hepatic Microsomal BDZ Activity in AG-Treated Sensitized Mice. We studied participation of allergy-induced NO in microsomal BDZ N-oxygenation activity suppressed by primary and secondary sensitization. Chronic AG treatment restored the BDZ activity suppressed in PS7 and SS7 mice (Fig. 6C ). When AG was injected in salinetreated (control) mice, hepatic BDZ activity was 104.9±6.5% and 97.9±2.5% of salinetreated mice. This result indicated that AG did not interact with FMO1 and FMO3
isoforms.
Discussion
FMO enzymes play significant roles in hepatic metabolism of drugs such as nicotine, chlorpromazine, clozapine, cimetidine and tamoxifen (Cashman et al., 1992 (Cashman et al., , 1993 Bhamre et al., 1995; Tugnait et al., 1997; Mani et al., 1993) . In allergic diseases, little is known about interactions between chemical mediators and FMO enzymes.
Concerning allergic disease-induced mediators, our recent study reported that the gas messenger NO markedly altered pharmacokinetics of major CYP-metabolic capacity- Functional FMO1, FMO3, and FMO5 proteins are expressed in the mouse liver (Cherrington et al., 1998) . As shown in Fig. 2A and B , we also confirmed the expression of hepatic FMO1 and FMO3 proteins in ICR female mice. Cherrington et al. (1998) showed that IMP was a much better substrate for FMO1 than for FMO3 and FMO5 in hepatic microsomes of mice. Furthermore, in FMO1 gene-deficient mice, the FMO1 isoform plays an important role in IMP metabolism (Hernandez et al., 2009) . Therefore, we selected IMP as a mouse FMO1 substrate. Concerning FMO3 substrates, BDZ is often used as in vitro probe of human and mouse FMO3-dependent metabolism (Fisher et al., 2002) . The recombinant FMO3 enzyme has a one-half lower Vmax (maximal velocity)/Km (Michaelis-Menten constant) value (intrinsic clearance) in BDZ N-oxide formation than the recombinant FMO1 enzyme (Stömer et al., 2000) . The recombinant FMO5 enzyme does not participate in BDZ metabolism. In recombinant human FMO3, trimethylamine, methimazole, and tozasertib strongly suppress BDZ N-oxygenation activity by 40-50% among well-known 41 FMO3 substrates including cimetidine and nicotine (Shimizu et al., 2015) . However, Siddens et al. (2008) showed that methimazole was metabolized by mouse FMO1, FMO2, and FMO3. Tozaserib, as well as BDZ, is reported to be a probe for FMO1 and FMO3 in humans and experimental animals (Yamazaki et al., 2014) . As far as we know, FMO3-specific substrates, except for endogenous trimethylamine, have not been reported in mice. Unfortunately, since we had no instruments for trimethylamine analysis, FMO3 activity was estimated from the data of BDZ N-oxygenation and specific IMP oxidation.
Unlike microsomal IMP-metabolic activity, PS7 and SS7 mice showed differential (Fig. 1) . In Western blot analysis, primary and secondary sensitization did not significantly alter the expression level of the FMO1 and FMO3 proteins (Fig. 2) . Park et al (1999) showed that hepatic FMO1 enzyme activity and contents were greatly suppressed by lipopolysaccharide (LPS), and this was at least partially prevented by treatment with inducible NOS (iNOS) inhibitor. The targets of LPS in up-regulating hepatic NO release are considered to be Kupffer and endothelial cells (Spolarics et al., 1993) . In Citrobacter rodentium-treated mice of a different inflammatory model, hepatic FMO1 and FMO3 mRNA levels were markedly down-regulated at day 10 post-treatment to 42% and 0.6% of controls, respectively (Zhang et al., 2009 ). These findings in Th1 cell-dependent inflammatory diseases differed from our data showing no changes in protein expression and activity of microsomal FMO1 (Figs. 1 and 2) . In this study, the differential suppression of FMO3 activity may be type 1 allergic disease-dependent. In differential suppression mechanism(s), it remains unclear whether direct cytokine stimulation and/or NO-releasing pathway prefer to suppress hepatic BDZ metabolism with irreversible and/or reversible inhibition.
The serum NO level was significantly enhanced by type 1 allergic diseases (Fig.   5B ). In general, NO is released from the vascular endothelium, Kupffer cells, platelets, mast cells, macrophages, nerve endings, and the brain (Garthwaite et al., 1988; Knowles et al., 1990) . NO is a small, unchanged free radical that diffuses freely in and out of cells microsomes from saline-treated mice, IMP N-oxidation activity was not suppressed by NO overproduction, however, BDZ N-oxide activity was significantly suppressed (Fig.   4 ). The differential suppression seemed to cause FMO3-dependent BDZ metabolism rather than FMO1-dependent BDZ metabolism. Additionally, the NO-derived inhibition capability and differential suppression may explain the changes in BDZ metabolic activity observed in PS7 and SS7 mice (Fig. 1) . Ryu et al. (2004) showed that recombinant human FMO3 activity (substrates: ranitidine, trimethylamine, and thiobenzamide) was directly suppressed by NO donors (SNP, SNAP, and Sin-1), resulting in the FMO3 activity being increased by incubation with AS. We were interested in reversible and/or irreversible inhibition(s) of microsomal BDZ metabolism down-regulated by NO overproduction. As shown in Fig. 4B , the direct NO-derived interaction was markedly reduced by AS treatment at an effective dose. Another reducing regent for -S-S adduct, dithiothreitol, did not restore NO-derived BDZ N-oxygenation activity to control level (data not shown).
Unlike CYP enzymes, FMO enzymes cannot produce iron-nitrosyl complexes in molecules (Minamiyama et al., 1997) . Since AS reduces S-nitroso adduct (S-NO adduct)
only (Xian et al., 2000) , we speculated that the direct effect of NO was related to protein S-nitrosyl cysteine, but not nitration of protein tyrosine residues (irreversible and stable adducts known as a marker of NO-mediated tissue damage), possibly leading to reversible suppression of FMO3-dependent BDZ activity. Protein S-nitrosylation is reported to be enhanced by NOS activation (Iwakiri and Kim, 2015) . In this study, we performed the AS treatment to characterize a suppression mechanism of FMO3-metabolic BDZ activity.
Hepatic NOS family is classified as constitutively expressed endothelial NOS (eNOS), neuronal NOS (nNOS), and iNOS (Knowles et al., 1990) . Eum et al. (2006) showed that iNOS-derived NO mediated hepatocellular damage. Hepatic eNOS is mainly expressed in sinusoidal endothelial cells and endothelial cells of the hepatic artery, portal vein, and central vein (Iwakiri and Kim, 2015; McNaughton et al., 2002) . Miyoshi et al. (2005) reported that iNOS played an important role in the elevation of plasma NOx by endotoxin, although the slight NOx elevation in plasma of TNF- -/mice was induced by eNOS enzyme. During endotoxemic shock and LPS-stimulated inflammation (Th1dependent pathway), it is believed that Kupffer cells are the main source of NO (Alexander, 1998) . Of interest, Takagi et al. (2007) demonstrated that hepatic iNOS expression was completely absent in TNF- -/mice. Bidri et al. (2001) showed that mast cells elicited sustained NO production, possibly through participation of a positive amplification loop via TNF- release, since FcRI-triggering induces TNF- release (Gordon and Galli, 1991) . Concerning other iNOS-stimulated cytokines, IL-1 is not essential for the induction of iNOS in hepatocytes of IL-1/ double-knockout mice (Takagi et al., 2007) . IL-1, IL-6 and interferon- are well-known to suppress the protein levels and activities of CTP1A2, CYP2C, CYP2E1, and CYP3A (Abdel-Razzak et al., 1993) , completely differing from our recent data (Tanino et al., 2016) . Therefore, we focused on hepatic TNF- activation among the iNOS-stimulated cytokines. As shown in Fig. 3B , PS7 and SS7 mice showed a 4-fold and 10-fold increase in hepatic TNF- mRNA levels, respectively. Although iNOS is not constitutively expressed under normal conditions, PS7 and SS7 mice showed significantly enhanced hepatic iNOS mRNA levels (Fig. 3A) . These results may be helpful in understanding a NO-produced pathway of the allergy-suppressed BDZ N-oxide activity. We further evaluated iNOS-dependent NO production in type 1 allergic mice. In PS7 and SS7 mice, a selective iNOS inhibitor, AG, completely suppressed the high serum NO levels (Fig. 6B ), and restored BDZ N-oxide activity to control levels ( Fig 6C) . After AS was incubated with hepatic microsomes from DMD/2017/076570 20 PS7 and SS7 mice, BDZ N-oxygenation returned to control levels (Fig. 5 ). Therefore, our results suggest that iNOS-derived NO participates in the formation of reversible -S-NO adducts, resulting in BDZ N-oxide activity suppressed in type 1 allergic mice.
In conclusion, we showed that the onset of IgE-mediated allergic diseases differentially suppressed the metabolic activity of clinically significant FMO3 enzyme.
This differential suppression related to post-translational interaction (cysteine-thiols Snitrosylation) with NO overproduced by hepatic iNOS activation, and our findings may suggest marked changes in hepatic FMO3-metabolic capacity-limited drug pharmacokinetics. This study would provide a first step towards clarifying the mechanisms of drug-disease interactions in allergic diseases via the Th2 cell-dependent pathway.
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Hormonal regulation of microsomal flavin-containing monooxygenase activity by sex steroids and growth hormone in co-cultured adult male rat hepatocytes. The protein expression is expressed in terms of percentage of 6-week-old mice (6-wk) before primary sensitization. 7-wk: the control mice for PS7 mice. 8-wk:
Biochem
the control mice for SS7 mice. All samples were loaded in triplicate. 
